QIAGEN N.V. $QGEN Shares Purchased by Rehmann Capital Advisory Group

Rehmann Capital Advisory Group increased its holdings in shares of QIAGEN N.V. (NYSE:QGEN) by 45.6% during the second quarter, HoldingsChannel.com reports. The fund owned 7,914 shares of the company’s stock after buying an additional 2,480 shares during the period. Rehmann Capital Advisory Group’s holdings in QIAGEN were worth $380,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Cullen Frost Bankers Inc. boosted its position in QIAGEN by 13,144.4% during the second quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock worth $57,000 after acquiring an additional 1,183 shares during the last quarter. Allianz Asset Management GmbH boosted its position in QIAGEN by 366.7% during the second quarter. Allianz Asset Management GmbH now owns 994,697 shares of the company’s stock worth $47,470,000 after acquiring an additional 781,561 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in QIAGEN by 10.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 7,078 shares of the company’s stock worth $340,000 after acquiring an additional 652 shares during the last quarter. Yousif Capital Management LLC boosted its position in QIAGEN by 3.7% during the second quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock worth $301,000 after acquiring an additional 222 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in QIAGEN by 11.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,732,963 shares of the company’s stock worth $131,756,000 after acquiring an additional 287,322 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

QIAGEN Stock Performance

Shares of QGEN stock opened at $49.37 on Friday. The firm’s 50 day moving average price is $47.00 and its 200-day moving average price is $46.10. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. QIAGEN N.V. has a one year low of $37.63 and a one year high of $51.88. The firm has a market cap of $10.97 billion, a P/E ratio of 29.17, a P/E/G ratio of 2.59 and a beta of 0.66.

QIAGEN (NYSE:QGEN) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 EPS for the quarter, hitting the consensus estimate of $0.60. QIAGEN had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $533.54 million for the quarter, compared to analyst estimates of $523.97 million. During the same period in the prior year, the business posted $0.55 EPS. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. As a group, equities research analysts predict that QIAGEN N.V. will post 2.26 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on QGEN. Cowen reiterated a “hold” rating on shares of QIAGEN in a report on Thursday, August 7th. Barclays set a $53.00 target price on shares of QIAGEN and gave the company an “overweight” rating in a report on Thursday, October 2nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of QIAGEN in a report on Wednesday, October 8th. UBS Group boosted their target price on shares of QIAGEN from $48.00 to $50.00 and gave the company a “neutral” rating in a report on Thursday, August 7th. Finally, Wall Street Zen lowered shares of QIAGEN from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Three investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.